Trials / Recruiting
RecruitingNCT06751992
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Conversion to extended-release tacrolimus | Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment |
| DRUG | Maintenance of immediate-release tacrolimus | Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment |
Timeline
- Start date
- 2026-03-17
- Primary completion
- 2027-05-01
- Completion
- 2027-10-01
- First posted
- 2024-12-30
- Last updated
- 2026-03-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06751992. Inclusion in this directory is not an endorsement.